Childhood Atopic Dermatitis Often Persists into Adulthood

Abstract

Little has been reported about the natural history of atopic dermatitis (AD). When topical calcineurin inhibitors were approved for AD treatment, the FDA required manufacturers to conduct post-marketing safety studies. One such effort is the Pediatric Eczema Elective Registry (PEER), which enrolled patients aged 2 to 17 years with mild-to-moderate AD who had used pimecrolimus cream for >42 days in the prior 6 months; …